<DOC>
	<DOCNO>NCT01183234</DOCNO>
	<brief_summary>The purpose study assess bioequivalence 2 capsule strength .</brief_summary>
	<brief_title>SPD544 High Strength Bioequivalence Study</brief_title>
	<detailed_description>This randomise , open-label , two-period , single dose , crossover bioequivalence study healthy subject fast condition assess bioequivalence 1 x 60 mg capsule methylphenidate compare 2 x 30 mg capsule methylphenidate . Pharmacokinetics safety assess .</detailed_description>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Inclusion criterion : 1 . Healthy subject , age 1855 year inclusive time consent . 2 . Subject must willing comply applicable contraceptive requirement protocol : Male , Nonpregnant , nonlactating female must &gt; 90 day postpartum nulliparous . 3 . Body Mass Index ( BMI ) 18.5 30.0kg/mÂ² inclusive . This inclusion criterion assess Screening visit . 4 . Satisfactory medical assessment clinically significant relevant abnormality medical history , physical examination , vital sign , ECG , clinical laboratory evaluation ( haematology , biochemistry , urinalysis ) assess Investigator . 5 . Ability provide write , personally sign date informed consent participate study . 6 . An understanding , ability willingness fully comply study procedure restriction . 7 . Ability swallow investigational medicinal product ( IMPs ) . Exclusion criterion : 1 . Current recurrent disease ( e.g. , cardiovascular , renal , liver , gastrointestinal , malignancy condition ) could affect action , absorption , disposition IMPs , could affect clinical laboratory assessment . 2 . Current relevant history physical psychiatric illness , medical disorder may require treatment make subject unlikely fully comply requirement study complete study , condition present undue risk IMPs study procedure . 3 . Current use medication ( include prescription , overthecounter [ OTC ] , herbal , homeopathic preparation ) exception hormone replacement therapy hormonal contraceptive and/or occasional dose nonsteroidal antiinflammatory ( NSAID ) , paracetamol ( current use define use within 14 day first dose IMP ) . 4 . History hypertension rest sit systolic blood pressure &gt; 139mmHg diastolic blood pressure &gt; 89mmHg . 5 . History seizure ( infantile febrile seizure ) , tic disorder , current diagnosis and/or family history Tourette 's Disorder . 6 . Known history symptomatic cardiovascular disease , advanced arteriosclerosis , structural cardiac abnormality , cardiomyopathy , serious heart rhythm abnormality , coronary artery disease , transient ischaemic attack stroke , serious cardiac problem may place increased vulnerability sympathomimetic effect stimulant drug . 7 . Family history sudden cardiac death ventricular arrhythmia . 8 . Known cerebrovascular disorder cerebral aneurysm , vascular abnormality include vasculitis history stroke . 9 . Diagnosis glaucoma . 10 . Diagnosis phaeochromocytoma . 11 . Current abnormal thyroid function , define abnormal screening thyroid stimulate hormone ( TSH ) thyroxine ( T4 ) . 12 . Current mark anxiety , tension and/or agitation . 13 . History alcohol substance abuse within last year . 14 . A positive screen alcohol drug abuse Screening Day 1 Treatment Period 1 . 15 . Male subject consume 3 unit alcohol per day . Female subject consume 2 unit alcohol per day . 16 . A positive human immunodeficiency virus ( HIV ) antibody screen , Hepatitis B surface antigen ( HBsAg ) , Hepatitis C virus ( HCV ) antibody screen . 17 . Use tobacco form ( e.g. , smoke chew ) nicotinecontaining product form ( e.g. , gum , patch ) within 30 day prior Screening visit . 18 . Routine consumption 300mg caffeine per day subject experience caffeine withdrawal headache history caffeine withdrawal headache . 19 . Donation blood blood product ( e.g. , plasma platelet ) within 90 day prior first dose IMP .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>